Navigation Links
FDA Accords Priority Review For Pediatric Crohn's Disease Drug

The U.S. Food and Drug Administration (FDA) has decided to accord a priority review for the drug REMICADE (R) (infliximab) to be used in the treatment of pediatric// Crohn's disease, the drug's manufacturer Centocor, Inc. announced today. Crohn's disease affects the gastrointestinal tract and causes diarrhea, fever, abdominal pain and weight loss. As of now there is no drug to treat children who develop this condition. Centocor had filed a supplemental Biologics License Application (sBLA), which was accepted by the FDA.

The filing is based primarily on Phase 3 study results showing the unprecedented efficacy of REMICADE in the treatment of children with moderately to severely active Crohn's disease. In the REACH (a Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF Monoclonal Antibody REMICADE in Pediatric Subjects with Moderate to Severe Crohn's Disease) trial, nearly 90 percent (88.4 percent) of pediatric patients with moderately to severely active Crohn's disease who had an inadequate response to conventional therapy achieved clinical response at week 10 when treated with REMICADE. Nearly two-thirds (63.5 percent) of the patients who were randomized to treatment with REMICADE every 8 weeks were in clinical response at one year. Additionally, more than half of the patients treated with REMICADE every 8 weeks were in clinical remission at the end of one year.

"We are extremely pleased by the results of the REACH trial and by the FDA's decision to accept the application with a Priority Review," said Jerome A. Boscia, MD, Senior Vice President, Clinical Research and Development, Centocor, Inc. "REMICADE, if approved for the treatment of pediatric Crohn's disease, would represent a major advancement for children with this serious condition. We look forward to working closely with the FDA as it reviews these data for approval."

Priority Review is granted by the FDA to products that are considered to be a potential therapeutic advance over current therapies. Acceptance of the sBLA filing does not mean that a license has been issued for this indication nor does it represent any evaluation of the adequacy of the data submitted in the sBLA. REMICADE was FDA-approved in 1998 as the first biologic treatment for adults with moderate to severe Crohn's disease. In September 2005, REMICADE also became the first approved biologic treatment for moderate to severe ulcerative colitis (UC), making it the only biologic indicated for the treatment of both types of inflammatory bowel disease (IBD) in adults. Contact: Michael Parks 215-983-8000 Centocor, Inc. Source: Eurekalert
'"/>




Related medicine news :

1. British MPs Say Prostate Cancer Receives Low Priority in the NHS
2. Funds Pumped In To Reduce Waiting List of Priority Patients
3. Children Health Care To Be Given Priority
4. Hypertension Not Given Priority during Treatment
5. Healthcare And Education Top Most Priority Of The Govt: Nitish
6. Global Health Issues To Take Priority In The Current G8 Summit In Russia
7. Consistent National Standards For Assessment Of Overseas Trained Doctors A Priority
8. Women and Children Issues Should Get Priority in India
9. WHO Urges Higher Priority for Neglected Diseases
10. COAG Must Make Combating Severe Allergies A National Priority
11. Priority Needs to Be Given to Maternal Health in Afghanistan
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2019)... ... 2019 , ... Dallas and Plano pet sitting company , Park Cities ... Saturday, February 9th from 2:30pm-3:30pm. The classes will run for 5 consecutive weeks, ... Dallas. , The series of classes will be taught by Park Cities ...
(Date:1/20/2019)... ... ... BackStory, an American history podcast produced by Virginia Humanities, releases “ When You ... What is the history of solitude in America? How are experiments on dolphins connected ... Pond have to teach us all in the digital age? On this episode of ...
(Date:1/20/2019)... ... 18, 2019 , ... Dr. Faye Jamali, a board-certified physician ... state-of-the-art medical boutique, Belle Marin Aesthetic Medicine, with a grand opening event on ... will enjoy refreshments, prize drawings, and exclusive event-only pricing. Attendees will meet the ...
(Date:1/20/2019)... ... January 19, 2019 , ... Bee Line Support, doesn't ... locations, certifying our management in the top infection prevention education , or ... stop at nothing to prove our unparalleled value. , This dedication to being ...
(Date:1/15/2019)... (PRWEB) , ... January 15, 2019 , ... Ophthalmic Consultants ... Valley Stream office to a new, larger space at 70 East Sunrise Highway, Suite ... serve the needs of its patients. , According to Gerard D’Aversa, MD, “After serving ...
Breaking Medicine News(10 mins):
(Date:1/15/2019)... ... January 15, 2019 , ... ... Resources (THR), the largest faith-based nonprofit health system in North Texas, deployed ... to MDsyncNET Co-Founder and CEO Brad Goldsmith, “We’re committed to providing Texas ...
(Date:1/14/2019)... ... January 14, 2019 , ... USpharma Ltd announced today it ... market. Bayer Consumer Care AG and its affiliates (collectively “Bayer”) have sold, ... USpharma. Since first being introduced in 1950, Cushion Grip was consistently a ...
(Date:1/14/2019)... ... ... The Villas at Heritage Woods of Centralia is celebrating 10 years of service ... Jan. 16. , “Since the beginning, The Villas has established itself as a wonderful ... that manages the community. , During the anniversary celebration, Administrator Tom Broughton will ...
Breaking Medicine Technology: